US EPA

19012 

Journal Article 

Review 

Kinetic and mechanistic data needs for a human phsiologically based pharmacokinetic (PBPK) model for acrylamide 

Andersen, ME; Scimeca, J; Olin, SS 

2005 

Yes 

Advances in Experimental Medicine and Biology
ISSN: 0065-2598 

561 

6 

117-125 

English 

16780359 

10.1021/tx050337k 

WOS:000238323200011 

A pharmacokinetic (PBPK) model has been developed for acrylamide (AMD) and its oxidative metabolite, glycidamide (GLY), in the rat based on available information. Despite gaps and limitations to the database, model parameters have been estimated to provide a relatively consistent description of the kinetics of acrylamide and glycidamide using a single set of values (with minor adjustments in some cases). Future kinetic and mechanistic studies will need to focus on the collection of key data for refining certain model parameters and for model validation, as well as for conducting studies that elucidate the mechanism of action. Development of a validated human AMD/GLY PBPK model capable of predicting target tissue doses at relevant dietary AMD exposures, in combination with expanding data on modes of action, should allow for a substantive improvement in the risk assessment of acrylamide in food. 

2-Chloro-1,3-butadiene; (1-Chloroethenyl)oxirane; Metabolism; Species differences 

1st International Symposium on Chemistry and Safety of Acrylamide in Food 

MAR 29-31, 2004